Summary
Whether a biologic response modifier or triple disease-modifying antirheumatic drug (DMARD) therapy should be the mainstay of treatment for patients with rheumatoid arthritis (RA) is a subject for debate. This article compares triple conventional DMARD therapy versus biologic agents for the treatment of RA.
- Rheumatoid Arthritis
- Rheumatology
- Exclusive Article - For home page
- Rheumatoid Arthritis
- © 2013 MD Conference Express®
Tools
Table of contents
Cited By...
- No citing articles found.